Neogen Total Liab vs Non Current Liabilities Total Analysis
NEOG Stock | USD 15.31 0.33 2.20% |
Neogen financial indicator trend analysis is infinitely more than just investigating Neogen recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neogen is a good investment. Please check the relationship between Neogen Total Liab and its Non Current Liabilities Total accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neogen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more detail on how to invest in Neogen Stock please use our How to Invest in Neogen guide.
Total Liab vs Non Current Liabilities Total
Total Liab vs Non Current Liabilities Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neogen Total Liab account and Non Current Liabilities Total. At this time, the significance of the direction appears to have totally related.
The correlation between Neogen's Total Liab and Non Current Liabilities Total is 1.0. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Non Current Liabilities Total in the same time period over historical financial statements of Neogen, assuming nothing else is changed. The correlation between historical values of Neogen's Total Liab and Non Current Liabilities Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Neogen are associated (or correlated) with its Non Current Liabilities Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Liabilities Total has no effect on the direction of Total Liab i.e., Neogen's Total Liab and Non Current Liabilities Total go up and down completely randomly.
Correlation Coefficient | 1.0 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Non Current Liabilities Total
Most indicators from Neogen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neogen current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neogen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more detail on how to invest in Neogen Stock please use our How to Invest in Neogen guide.At this time, Neogen's Enterprise Value is most likely to increase significantly in the upcoming years.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 243.0M | 406.0M | 463.9M | 487.1M | Total Revenue | 527.2M | 822.4M | 924.2M | 970.4M |
Neogen fundamental ratios Correlations
Click cells to compare fundamentals
Neogen Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Neogen fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 797.2M | 920.2M | 992.9M | 4.6B | 4.5B | 4.8B | |
Other Current Liab | 22.8M | 26.6M | 35.6M | 57.2M | 48.6M | 51.1M | |
Total Current Liabilities | 48.5M | 53.6M | 77.8M | 145.5M | 154.3M | 162.0M | |
Total Stockholder Equity | 725.2M | 840.4M | 887.4M | 3.1B | 3.1B | 3.3B | |
Property Plant And Equipment Net | 78.7M | 100.5M | 110.6M | 198.7M | 291.9M | 306.5M | |
Net Debt | (342.6M) | (379.8M) | 605.6M | 736.8M | 735.6M | 772.4M | |
Retained Earnings | 478.7M | 539.6M | 587.9M | 565.0M | 555.6M | 583.4M | |
Cash | 343.7M | 381.1M | 381.1M | 163.2M | 170.6M | 179.1M | |
Non Current Assets Total | 259.8M | 328.7M | 366.1M | 4.0B | 4.0B | 4.2B | |
Non Currrent Assets Other | 2.2M | 2.0M | 2.2M | 15.2M | 20.2M | 15.7M | |
Cash And Short Term Investments | 343.7M | 381.1M | 381.1M | 245.6M | 170.9M | 179.5M | |
Net Receivables | 84.7M | 91.8M | 99.7M | 153.3M | 173.0M | 181.7M | |
Common Stock Shares Outstanding | 105.7M | 107.1M | 108.0M | 188.9M | 216.5M | 227.3M | |
Liabilities And Stockholders Equity | 797.2M | 920.2M | 992.9M | 4.6B | 4.5B | 4.8B | |
Non Current Liabilities Total | 23.5M | 26.2M | 27.7M | 1.3B | 1.3B | 1.3B | |
Inventory | 95.1M | 100.7M | 122.3M | 133.8M | 189.3M | 198.7M | |
Other Current Assets | 14.0M | 35.7M | 47.5M | 53.3M | 56.0M | 58.8M | |
Other Stockholder Equity | 257.7M | 295.0M | 310.0M | 2.6B | 2.6B | 2.7B | |
Total Liab | 72.0M | 79.8M | 105.6M | 1.4B | 1.4B | 1.5B | |
Property Plant And Equipment Gross | 80.6M | 102.9M | 215.5M | 318.9M | 432.2M | 453.8M | |
Total Current Assets | 537.4M | 591.5M | 626.8M | 585.9M | 589.2M | 618.7M | |
Accumulated Other Comprehensive Income | (19.7M) | (11.4M) | (27.8M) | (33.3M) | (30.0M) | (28.5M) | |
Intangible Assets | 66.6M | 92.3M | 107.5M | 1.6B | 1.5B | 1.6B | |
Accounts Payable | 25.7M | 23.9M | 34.6M | 76.7M | 83.1M | 87.2M | |
Common Stock Total Equity | 8.5M | 17.2M | 17.2M | 34.6M | 39.8M | 41.8M | |
Short Term Investments | 277.4M | 305.5M | 336.6M | 82.3M | 325K | 308.8K | |
Common Stock | 8.5M | 17.2M | 17.2M | 34.6M | 34.7M | 32.9M | |
Other Liab | 22.6M | 26.2M | 27.7M | 375.7M | 432.1M | 453.7M | |
Other Assets | 2.2M | 2.0M | 4.8B | 15.2M | 1.0 | 0.95 | |
Good Will | 181.1M | 228.3M | 255.5M | 3.8B | 2.1B | 2.2B | |
Property Plant Equipment | 78.7M | 100.5M | 110.6M | 198.7M | 228.6M | 240.0M | |
Net Tangible Assets | 599.6M | 612.1M | 887.4M | 3.1B | 3.6B | 3.8B | |
Retained Earnings Total Equity | 478.7M | 539.6M | 587.9M | 565.0M | 649.8M | 382.8M |
Currently Active Assets on Macroaxis
When determining whether Neogen is a strong investment it is important to analyze Neogen's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neogen's future performance. For an informed investment choice regarding Neogen Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neogen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more detail on how to invest in Neogen Stock please use our How to Invest in Neogen guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neogen. If investors know Neogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.86) | Earnings Share (0.11) | Revenue Per Share 4.212 | Quarterly Revenue Growth (0.05) | Return On Assets 0.0085 |
The market value of Neogen is measured differently than its book value, which is the value of Neogen that is recorded on the company's balance sheet. Investors also form their own opinion of Neogen's value that differs from its market value or its book value, called intrinsic value, which is Neogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neogen's market value can be influenced by many factors that don't directly affect Neogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.